NUVL Nuvalent, Inc.
FY2025 10-K
Nuvalent, Inc. (NUVL) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model focused on biopharmaceutical development and innovation
- • No new products, services, or segments introduced or emphasized this year
Management Discussion & Analysis
- • Net loss $425.4M in 2025 vs $260.8M in 2024; operating cash outflow $275.2M vs $185.1M
- • Operating cash flow decline due to higher clinical, manufacturing, personnel expenses; stock-based comp $86.5M vs $60.6M
Risk Factors
- • FDA acceptance of NDA for zidesamtinib with PDUFA date September 18, 2026, critical regulatory milestone risk
- • Exposure to macroeconomic risks including inflation, interest rate fluctuations, and geopolitical tensions impacting funding access
Financial SummaryXBRL
Net Income
-$425M
ROE
-34.1%
Total Assets
$1.4B
EPS (Diluted)
$-5.85
Operating Cash Flow
-$275M
Source: XBRL data from Nuvalent, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Nuvalent, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.